The estimated Net Worth of Terry L Murdock is at least $3.75 Milion dollars as of 5 July 2024. Mr. Murdock owns over 2,475 units of G1 Therapeutics Inc stock worth over $912,726 and over the last 7 years he sold GTHX stock worth over $91,862. In addition, he makes $2,748,750 as Chief Operating Officer at G1 Therapeutics Inc.
Terry has made over 12 trades of the G1 Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,475 units of GTHX stock worth $6,212 on 5 July 2024.
The largest trade he's ever made was selling 8,151 units of G1 Therapeutics Inc stock on 13 May 2024 worth over $39,043. On average, Terry trades about 1,889 units every 108 days since 2017. As of 5 July 2024 he still owns at least 128,012 units of G1 Therapeutics Inc stock.
You can see the complete history of Mr. Murdock stock trades at the bottom of the page.
Terry L. Murdock serves as Chief Operating Officer of the Company. Mr. Murdock served as Vice President, Development Solutions of the Oncology Center for Excellence at IQVIA Holdings Inc. (formerly Quintiles IMS Holdings, Inc.), or IQVIA, from September 2014 to August 2015, and then as Vice President, Global Head of the Oncology Center for Excellence at IQVIA from August 2015 to July 2017. Prior to his tenure with IQVIA, Mr. Murdock served as President North America and a member of the board of directors of Ergomed Clinical Research, Inc., a wholly owned subsidiary of Ergomed plc, a publicly traded British pharmaceutical services company from 2012 to August 2014. Mr. Murdock also was Senior Vice President of ILEX Oncology Inc., or ILEX, and later Genzyme Corporation, a biotechnology company, following its acquisition of ILEX from 2001 to May 2012 and Vice President of Research at The US Oncology Network, a healthcare services company from 1995 to 2001.
As the Chief Operating Officer of G1 Therapeutics Inc, the total compensation of Terry Murdock at G1 Therapeutics Inc is $2,748,750. There are 3 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.
Terry Murdock is 60, he's been the Chief Operating Officer of G1 Therapeutics Inc since 2019. There are 9 older and 16 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.
Terry's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.
Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman a Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
G1 Therapeutics Inc executives and other stock owners filed with the SEC include: